Literature DB >> 27150611

Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms.

David S Klimstra1,2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27150611     DOI： 10.1007/s12020-016-0966-x

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  13 in total

1.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

2.  Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Authors:  Laura H Tang; Brian R Untch; Diane L Reidy; Eileen O'Reilly; Deepti Dhall; Lily Jih; Olca Basturk; Peter J Allen; David S Klimstra
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

3.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

Authors:  David S Klimstra; Irvin R Modlin; N Volkan Adsay; Runjan Chetty; Vikram Deshpande; Mithat Gönen; Robert T Jensen; Mark Kidd; Matthew H Kulke; Ricardo V Lloyd; Cesar Moran; Steven F Moss; Kjell Oberg; Dermot O'Toole; Guido Rindi; Marie E Robert; Saul Suster; Laura H Tang; Chin-Yuan Tzen; Mary Kay Washington; Betram Wiedenmann; James Yao
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

5.  Classification of low-grade neuroendocrine tumors of midgut and unknown origin.

Authors:  Susanne Van Eeden; Pascal F H J Quaedvlieg; Babs G Taal; G Johan A Offerhaus; Cornelis B H W Lamers; Marie-Louise F Van Velthuysen
Journal:  Hum Pathol       Date:  2002-11       Impact factor: 3.466

6.  Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?

Authors:  Vinciane Rebours; Jacqueline Cordova; Anne Couvelard; Monique Fabre; Laurent Palazzo; Marie Pierre Vullierme; Olivia Hentic; Alain Sauvanet; Alain Aubert; Pierre Bedossa; Philippe Ruszniewski
Journal:  Dig Liver Dis       Date:  2015-06-20       Impact factor: 4.088

7.  Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.

Authors:  Aldo Scarpa; William Mantovani; Paola Capelli; Stefania Beghelli; Letizia Boninsegna; Rossella Bettini; Francesco Panzuto; Paolo Pederzoli; Gianfranco delle Fave; Massimo Falconi
Journal:  Mod Pathol       Date:  2010-03-19       Impact factor: 7.842

Review 8.  Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.

Authors:  Nitya Raj; Diane Reidy-Lagunes
Journal:  Hematol Oncol Clin North Am       Date:  2015-10-23       Impact factor: 3.722

Review 9.  Pathologic Classification of Neuroendocrine Neoplasms.

Authors:  David S Klimstra
Journal:  Hematol Oncol Clin North Am       Date:  2015-10-24       Impact factor: 3.722

10.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Authors:  H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976
View more
  4 in total

1.  G3 GEP NENs category: are basic and clinical investigations well integrated?

Authors:  Massimo Milione; Nicola Fazio
Journal:  Endocrine       Date:  2017-07-21       Impact factor: 3.633

2.  KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?

Authors:  Federica Grillo; Luca Valle; Diego Ferone; Manuela Albertelli; Maria Pia Brisigotti; Giuseppe Cittadini; Alessandro Vanoli; Roberto Fiocca; Luca Mastracci
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

3.  Quantitative Computed Tomography Image Analysis to Predict Pancreatic Neuroendocrine Tumor Grade.

Authors:  Alessandra Pulvirenti; Rikiya Yamashita; Jayasree Chakraborty; Natally Horvat; Kenneth Seier; Caitlin A McIntyre; Sharon A Lawrence; Abhishek Midya; Maura A Koszalka; Mithat Gonen; David S Klimstra; Diane L Reidy; Peter J Allen; Richard K G Do; Amber L Simpson
Journal:  JCO Clin Cancer Inform       Date:  2021-06

4.  Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.

Authors:  Alessandra Pulvirenti; Nitya Raj; Sara Cingarlini; Antonio Pea; Laura H Tang; Claudio Luchini; Joanne F Chou; Elisabetta Grego; Ioana Marinova; Marinela Capanu; Luca Landoni; Aldo Scarpa; Peter J Allen; David S Klimstra; Diane L Reidy-Lagunes
Journal:  Pancreas       Date:  2021-02-01       Impact factor: 3.243
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.